Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.86
+0.02 (0.26%)
Sep 4, 2025, 3:43 PM - Market open
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
The 7 analysts that cover Xeris Biopharma Holdings stock have a consensus rating of "Strong Buy" and an average price target of $8.00, which forecasts a 1.78% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $11.
Price Target: $8.00 (+1.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $7 → $9 | Buy | Maintains | $7 → $9 | +14.50% | Aug 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $10 | Strong Buy | Initiates | $10 | +27.23% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $6.5 → $11 | Strong Buy | Maintains | $6.5 → $11 | +39.95% | Aug 8, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | +1.78% | Aug 8, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $6 → $7 | Buy | Maintains | $6 → $7 | -10.94% | May 9, 2025 |
Financial Forecast
Revenue This Year
292.20M
from 203.07M
Increased by 43.89%
Revenue Next Year
351.82M
from 292.20M
Increased by 20.40%
EPS This Year
-0.07
from -0.37
EPS Next Year
0.23
from -0.07
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 303.6M | 386.1M | |||
| Avg | 292.2M | 351.8M | |||
| Low | 277.1M | 319.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 49.5% | 32.1% | |||
| Avg | 43.9% | 20.4% | |||
| Low | 36.4% | 9.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.01 | 0.62 | |
| Avg | -0.07 | 0.23 | |
| Low | -0.16 | -0.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.